• Blood biomarker may indicate Parkinson's progression
    Blood biomarker may indicate Parkinson's progression

Bioanalytical

Blood biomarker may indicate Parkinson's progression

Sep 19 2013

A specific blood biomarker may give experts an indication of cognitive decline and the progression of Parkinson's disease in patients, the results of a new study have indicated.

A specific mutation known as GBA that leads to early onset of Parkinson's disease and severe cognitive impairment was found to also alter how specific lipids, ceramides and glucosylceramides are metabolised.

Researchers from the Mayo Clinic found that Parkinson's patients who do not carry the genetic mutation have higher levels of these lipids in the blood, while those who have Parkinson's and high blood levels are more likely to have cognitive impairment and dementia.

The research, which has been published online in the journal PLOS ONE, suggests that analysing this could lead to important warnings for people suffering from Parkinson's, which is the second most common neurodegenerative disease after Alzheimer's.

Dr Michelle Mielke, a Mayo Clinic researcher and first author of the study, said there is currently no biomarker to gauge who is going to develop the disease, or and who is going to develop cognitive impairment after developing Parkinson's.

She added that early identification of Parkinson's patients at greatest risk of developing dementia is important for preventing or delaying the onset and progression of cognitive symptoms, and changing these blood lipids could be a way to stop the progression of the disease.

According to the experts, it may be possible for this blood lipid marker to help predict who will develop Parkinson's disease.

"There is currently no cure for Parkinson's, but the earlier we catch it - the better chance we have to fight it. It's particularly important we find a biomarker and identify it in the preclinical phase of the disease, before the onset even begins," Dr Mielke stated.

The researchers are currently investigating blood-based biomarkers for Parkinson's disease, as blood tests are less invasive and cheaper than a brain scan or spinal tap, which are often used when researching the disease.


Digital Edition

Chromatography Today - Buyers' Guide 2022

October 2023

In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions

Events

analytica 2024

Apr 09 2024 Munich, Germany

Korea Lab 2024

Apr 23 2024 Kintex, South Korea

Korea Chem 2024

Apr 23 2024 Seoul, South Korea

AOCS Annual Meeting & Expo

Apr 28 2024 Montreal, Quebec, Canada

SETAC Europe

May 05 2024 Seville, Spain

View all events